Report Description Table of Contents How Are Clinical Applications and Diagnostic Advancements Shaping the Global Preeclampsia Laboratory Testing Market? – (Updated On: 12th-Oct-2026) The Global Preeclampsia Laboratory Testing Market was estimated at USD 646.5 million in 2025 and is projected to reach USD 1.13 billion by 2032, expanding at a CAGR of 8.33% during 2026–2032, according to Strategic Market Research. Market growth is supported by increasing identification of pregnancy-related hypertension, routine laboratory monitoring, and growing adoption of advanced preeclampsia blood tests. Demand spans urine protein tests, platelet counts, liver and kidney function tests, placental biomarker assays, diagnostic reagents, and automated laboratory analyzers. Specialized blood tests are strengthening preeclampsia risk assessment in clinical laboratories. The international PROGNOSIS study enrolled 1,050 pregnant women with suspected preeclampsia, including 550 women in its validation group. The sFlt-1/PlGF ratio test demonstrated a 99.3% negative predictive value for ruling out preeclampsia within one week. According to the CDC, 377,267 U.S. births involved gestational hypertension in 2024, accounting for 10.4% of all births, compared with 361,780 cases in 2023. FDA-cleared biomarker tests are expanding the commercial availability of specialized preeclampsia laboratory testing in the United States. Thermo Fisher Scientific received FDA authorization for its B·R·A·H·M·S sFlt-1/PlGF KRYPTOR Test System in May 2023, followed by Roche Diagnostics' Elecsys sFlt-1 and PlGF assays in February 2025. Roche also reported more than 4,000 cobas analyzers installed across the United States, providing an existing equipment base for compatible laboratory applications. These regulatory developments create opportunities for biomarker reagent suppliers, automated immunoassay manufacturers, and hospital laboratories introducing specialized preeclampsia risk-assessment services. Market Segment Analysis: Which Subsegments Lead the Preeclampsia Laboratory Testing Market, and Where Are the Fastest-Growing Opportunities? By Test Type: Proteinuria Anchors Revenue as sFlt-1/PlGF Testing Expands Risk Assessment Largest Subsegment: Proteinuria Testing Proteinuria testing held the leading position in the Preeclampsia Laboratory Testing Market, accounting for an estimated 62% market share, equivalent to USD 400.83 million in 2025, and is projected to expand at a CAGR of 7.0% during 2026–2032. Urine protein assessment remains an important component of preeclampsia evaluation, particularly among pregnant women presenting with hypertension. Although current clinical guidelines permit diagnosis without proteinuria when other signs of maternal organ dysfunction are present, proteinuria testing continues to support clinical assessment and disease monitoring. Fastest-Growing Subsegment: sFlt-1/PlGF Ratio Testing sFlt-1/PlGF Ratio Testing accounted for an estimated 38% market share, valued at USD 245.67 million in 2025, and is projected to record the fastest CAGR of 10.3% during 2026–2032. The test measures the balance between soluble fms-like tyrosine kinase-1 (sFlt-1), an anti-angiogenic protein, and placental growth factor (PlGF), a pro-angiogenic protein, to assess preeclampsia risk. Its clinical use in identifying suspected preeclampsia and supporting short-term risk prediction strengthens its position in maternal healthcare and laboratory testing. By Biomarker: Urinary Protein Leads While Angiogenic Assays Gain Clinical Momentum Largest Subsegment: Urinary Protein Biomarkers Urinary Protein Biomarkers accounted for an estimated 60% share of the Preeclampsia Laboratory Testing Market in 2025, representing USD 387.90 million, and are projected to expand at a CAGR of 6.9% during 2026–2032. Urinary protein testing supports preeclampsia diagnosis by identifying excessive protein excretion associated with renal endothelial dysfunction in pregnant women after 20 weeks of gestation. Its established role in evaluating suspected preeclampsia, widespread availability in clinical laboratories, and continued use alongside blood pressure assessment reinforce its leading market position. Fastest-Growing Subsegment: Angiogenic Biomarkers Angiogenic biomarkers accounted for an estimated 40% of the Preeclampsia Laboratory Testing Market, valued at USD 258.60 million in 2025, and are projected to register the fastest CAGR of 10.25% during 2026–2032. Their leading position is supported by increasing clinical adoption of placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) testing, which identifies imbalances in placental proteins before clinical symptoms emerge. Early risk assessment, improved diagnostic accuracy, and timely identification of preeclampsia complications are strengthening their role in maternal healthcare. By Technology: Established Immunoassays Lead as Automated Chemiluminescence Platforms Expand Largest Subsegment: Immunoassays Immunoassays accounted for an estimated 56% share of the Preeclampsia Laboratory Testing Market, representing USD 362.04 million in 2025, and are projected to expand at a CAGR of 7.1% during 2026–2032. Their leading position is supported by the clinical use of blood-based angiogenic biomarkers, particularly sFlt-1 and PlGF, to assess placental dysfunction and identify pregnant women at risk of developing preeclampsia. Increasing adoption of sFlt-1/PlGF ratio testing supports early risk stratification, clinical decision-making, and monitoring of suspected preeclampsia. Fastest-Growing Subsegment: Automated Chemiluminescence Immunoassays Automated Chemiluminescence Immunoassays (CLIAs) accounted for an estimated 44% of the Preeclampsia Laboratory Testing Market, valued at USD 284.46 million in 2025, and are projected to register the fastest CAGR of 9.8% during 2026–2032. Automated CLIA platforms measure placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1), enabling assessment of angiogenic imbalance associated with preeclampsia. Their growing integration into hospital laboratories supports early risk assessment, clinical diagnosis, and monitoring of pregnant women with suspected preeclampsia. By Sample Type: Urine Testing Leads Revenue While Blood Biomarkers Drive Faster Growth Largest Subsegment: Urine Samples Urine samples accounted for the largest share of the Preeclampsia Laboratory Testing Market at approximately 57% in 2025, corresponding to a market value of USD 368.51 million, and are projected to grow at a CAGR of 6.8% during 2026–2032. Their leading position is supported by the widespread use of urine protein testing to identify and quantify proteinuria, an important indicator of kidney involvement in preeclampsia after 20 weeks of pregnancy. Routine urinalysis and urine protein-to-creatinine ratio testing support clinical evaluation and ongoing maternal monitoring. Fastest-Growing Subsegment: Blood Samples Blood Samples accounted for an estimated 43% share, generating USD 277.99 million in 2025 revenue, and are projected to register the fastest CAGR of 10.1% during 2026–2032. Blood-based laboratory testing includes platelet counts, liver enzymes, creatinine, and angiogenic biomarkers. Its faster expansion reflects the increasing commercial importance of specialized biomarker assays alongside conventional maternal organ-function assessment. By Application: Diagnosis Leads Spending as Earlier Risk Prediction Expands Testing Demand Largest Subsegment: Preeclampsia Diagnosis Preeclampsia Diagnosis accounted for an estimated 67% of the Preeclampsia Laboratory Testing Market, representing USD 433.16 million in 2025, and is projected to expand at a CAGR of 7.1% during 2026–2032. Clinical diagnosis involves newly developed, persistent hypertension of ≥140/90 mmHg after 20 weeks of pregnancy, accompanied by proteinuria or other evidence of organ dysfunction, including low platelet counts or elevated liver enzymes. Routine prenatal screening, confirmatory laboratory assessments, and timely identification of maternal complications support its leading market position. Fastest-Growing Subsegment: Early Risk Assessment and Prediction Early Risk Assessment and Prediction accounted for an estimated 33% market share, valued at USD 213.34 million in 2025, and is projected to register the fastest CAGR of 10.7% during 2026–2032. Preeclampsia laboratory testing enables early identification of high-risk pregnancies through maternal blood biomarkers and predictive screening before clinical symptoms emerge. Earlier detection supports timely preventive interventions, closer maternal monitoring, and improved pregnancy management, helping healthcare providers reduce the likelihood of severe maternal complications and adverse fetal outcomes. By End User: Hospitals Anchor Demand While Diagnostic Laboratories Expand Quantitative Testing Largest Subsegment: Hospitals Hospitals dominated the Preeclampsia Laboratory Testing Market with an estimated 72% market share, valued at USD 465.48 million in 2025, and are projected to expand at a CAGR of 7.9% during 2026–2032. Their leading position reflects the concentration of high-risk pregnancies and emergency obstetric care in hospital settings, where rapid laboratory assessment is essential for identifying preeclampsia severity. Hospitals routinely perform platelet counts, liver and kidney function tests, urinary protein assessments, and angiogenic biomarker testing to guide maternal monitoring and timely clinical intervention. Fastest-Growing Subsegment: Diagnostic Laboratories Diagnostic Laboratories accounted for an estimated 28% share, equivalent to USD 181.02 million in 2025 revenue, and are projected to register the fastest CAGR of 9.3% during 2026–2032. Centralized laboratories provide proteinuria measurements, biochemical panels, and specialized pregnancy-associated biomarker assays. Expanding access to automated immunoassay platforms and referral testing arrangements presents opportunities for laboratories offering quantitative maternal health diagnostics. By Geography: North America Leads Adoption as Asia-Pacific Expands Maternal Diagnostics Largest Regional Market: North America North America held the largest share of the Preeclampsia Laboratory Testing Market at approximately 37% in 2025, representing a market value of USD 239.21 million, with an anticipated CAGR of 7.6% during 2026–2032. The region is witnessing increasing adoption of advanced preeclampsia laboratory testing, supported by the integration of predictive biomarkers such as the sFlt-1/PlGF ratio alongside conventional proteinuria assessment and maternal blood monitoring. Expanding high-risk pregnancy screening, improved access to specialized maternal healthcare, and earlier identification of preeclampsia are strengthening clinical testing adoption. Fastest-Growing Regional Market: Asia-Pacific Asia-Pacific accounted for an estimated 27% of the global Preeclampsia Laboratory Testing Market in 2025, valued at USD 174.56 million, and is projected to register the fastest regional CAGR of 10.1% during 2026–2032. Increasing emphasis on preventive prenatal care, expanding maternal health screening programs, and growing clinical research activities are strengthening the adoption of preeclampsia laboratory testing across the region. Greater availability of placental growth factor (PlGF) and sFlt-1/PlGF ratio testing is also supporting earlier risk assessment and improved clinical management of high-risk pregnancies. Which Companies Are Leading the Preeclampsia Laboratory Testing Market Through Biomarker Innovation and Diagnostic Platform Expansion? Thermo Fisher Scientific: FDA-Authorized KRYPTOR Testing Builds a Hospital Laboratory Advantage Thermo Fisher Scientific holds a strong competitive position in preeclampsia laboratory testing through its B·R·A·H·M·S KRYPTOR biomarker platform. In May 2023, the company received U.S. FDA authorization for its sFlt-1 and PlGF immunoassays, establishing the first FDA-authorized blood-based prognostic testing system of its kind for preeclampsia. The supporting PRAECIS study involved more than 700 pregnant women across 18 U.S. hospitals. Its KRYPTOR compact PLUS analyzer delivers results in less than 30 minutes, positioning the company to serve hospitals requiring timely assessment of patients at risk of severe preeclampsia. The authorization provides Thermo Fisher with an important competitive advantage in the U.S. hospital laboratory segment. Roche Diagnostics: Elecsys Biomarkers Expand Testing Across an Established Analyzer Network Roche Diagnostics strengthened its position in February 2025 when the U.S. FDA cleared its Elecsys sFlt-1/PlGF ratio test for assessing the risk of severe preeclampsia within two weeks among hospitalized pregnant women with hypertensive disorders. Roche reported an installed base of more than 4,000 cobas analyzers in the United States, providing an established laboratory infrastructure for introducing the assay. The company also reported that nearly 70% of women with an sFlt-1/PlGF ratio greater than 38 delivered within two weeks in the supporting clinical evidence. Roche's existing analyzer network offers an opportunity to expand adoption without requiring every hospital to invest in an entirely new diagnostic platform. Siemens Healthineers: Atellica and ADVIA Platforms Support an Emerging Biomarker Pipeline Siemens Healthineers is an important participant in the preeclampsia testing landscape through its Atellica IM and ADVIA Centaur laboratory platforms and its sFlt-1 and PlGF assay development portfolio. The company identifies preeclampsia as affecting approximately 2–8% of pregnancies, supporting the clinical need for more accessible laboratory risk assessment. Its Atellica IM assay specifications include a PlGF measuring range of 10–10,000 pg/mL and an sFlt-1 range of 15–85,000 pg/mL. Siemens could use its established immunoassay platform presence to compete for routine hospital testing volumes. However, its U.S. assay menu identifies these preeclampsia tests as under development and not commercially available, so its position should not be equated with the FDA-authorized offerings of Thermo Fisher and Roche. Other Notable Companies: Revvity: Supplies DELFIA Xpress sFlt-1 and PlGF testing solutions for prenatal screening and preeclampsia risk assessment, including a 96-test sFlt-1 assay kit, supporting recurring laboratory reagent demand in authorized markets. QuidelOrtho: Offers the Quidel Triage PlGF test for suspected preterm preeclampsia, producing results in approximately 15 minutes and serving decentralized maternal-care testing applications in markets where the product is authorized. Analyst Commentary: How Will Biomarker Adoption and Reimbursement Shape the Preeclampsia Laboratory Testing Market? The Preeclampsia Laboratory Testing Market is gaining commercial importance as maternity care shifts toward earlier risk identification and more evidence-based clinical decisions. The strongest opportunities lie in expanding sFlt-1/PlGF biomarker testing, integrating rapid immunoassays into hospital laboratory workflows, and improving access to testing for high-risk pregnancies. Wider clinical adoption will depend on regulatory approvals, reimbursement coverage, and stronger evidence that biomarker-guided assessment improves maternal care while reducing unnecessary hospital admissions and monitoring costs. Preeclampsia Laboratory Testing Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 646.5 Million Revenue Forecast in 2032 USD 1.13 Billion Overall Growth Rate CAGR of 8.33% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Test Type, By Biomarker, By Technology, By Sample Type, By Application, By End User, By Geography By Test Type Proteinuria Testing, sFlt-1/PlGF Ratio Testing By Biomarker Urinary Protein Biomarkers, Angiogenic Biomarkers By Technology Immunoassays, Automated Chemiluminescence Immunoassays By Sample Type Urine Samples, Blood Samples By Application Preeclampsia Diagnosis, Early Risk Assessment and Prediction By End User Hospitals, Diagnostic Laboratories By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Increasing identification of pregnancy-related hypertension, growing routine laboratory monitoring during pregnancy, rising adoption of sFlt-1/PlGF ratio testing, expansion of angiogenic biomarker testing, increasing demand for early preeclampsia risk assessment, adoption of automated immunoassay platforms, FDA authorization of specialized biomarker tests, expansion of high-risk pregnancy monitoring, and growing access to advanced maternal laboratory diagnostics Customization Option Available upon request Frequently Asked Question About This Report Q1. What are the main factors driving growth in the market? A1. Growth is being supported by wider prenatal screening, rising identification of pregnancy-related hypertension, and increasing use of biomarker-based testing. Automated laboratory platforms are also improving access to specialized risk assessment. Q2. What are the key trends shaping the industry? A2. The industry is moving toward sFlt-1/PlGF testing, automated chemiluminescence immunoassays, and earlier risk prediction. Hospitals are increasingly combining conventional proteinuria testing with blood-based angiogenic biomarkers. Q3. Why are angiogenic biomarkers gaining importance in the market? A3. Angiogenic biomarkers such as sFlt-1 and PlGF can improve short-term risk assessment in suspected preeclampsia. Their growing clinical use is helping laboratories identify placental dysfunction before severe complications develop. Q4. How is automation influencing the industry? A4. Automated immunoassay systems enable faster and more standardized biomarker measurement. Their integration into hospital laboratories supports higher testing volumes and more efficient maternal risk assessment. Q5. Which application is creating the strongest growth opportunity in the market? A5. Early risk assessment and prediction is projected to record the fastest application CAGR of 10.7% during 2026–2032. Its expansion is supported by predictive biomarker testing and increased focus on identifying high-risk pregnancies earlier. Q6. Why are diagnostic laboratories becoming more important in the industry? A6. Diagnostic laboratories are expanding their role through centralized biomarker testing, biochemical panels, and automated maternal health assays. Their ability to process specialized referral tests supports growing demand outside hospital laboratories. Q7. Which region is expected to record the fastest growth in the market? A7. Asia-Pacific is projected to record the fastest regional CAGR of 10.1% during 2026–2032. Growth is supported by expanding prenatal screening programs, improving maternal healthcare access, and increasing availability of PlGF and sFlt-1/PlGF testing. Sources: CDC/NCHS – 377,267 U.S. Births Involved Gestational Hypertension in 2024, Representing 10.4% of Births CDC – Gestational Hypertension: United States, 2016–2024 NEJM – PROGNOSIS Study: sFlt-1/PlGF Ratio ≤38 Delivered 99.3% Negative Predictive Value for Preeclampsia Within One Week NEJM – Predictive Value of the sFlt-1/PlGF Ratio in Women With Suspected Preeclampsia U.S. FDA – B·R·A·H·M·S sFlt-1/PlGF KRYPTOR Test System Authorized in May 2023 FDA – B·R·A·H·M·S sFlt-1/PlGF KRYPTOR De Novo Record Thermo Fisher Scientific – PRAECIS Study Included 700+ Pregnant Women Across 18 U.S. Hospitals Thermo Fisher – FDA Clearance of Preeclampsia Immunoassays U.S. FDA – Roche Elecsys sFlt-1 and PlGF Assays Received 510(k) Clearance in February 2025 FDA – Roche Elecsys sFlt-1 and PlGF, K241453 Roche Diagnostics – Elecsys sFlt-1/PlGF Ratio; 4,000+ cobas Analyzers Installed in the United States Roche – Elecsys sFlt-1/PlGF FDA Clearance ACOG – Preeclampsia Diagnostic Work-Up Includes Proteinuria, Platelet Count, Kidney Function and Liver Function Testing ACOG – Gestational Hypertension and Preeclampsia Practice Bulletin Siemens Healthineers – Atellica IM sFlt-1 and PlGF Assay Performance and Preeclampsia Biomarker Testing Siemens Healthineers – sFlt-1 and PlGF Assays for Preeclampsia Table of Contents - Global Preeclampsia Laboratory Testing Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Test Type, Biomarker, Technology, Sample Type, Application, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Test Type, Biomarker, Technology, Sample Type, Application, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Test Type, Biomarker, Technology, Sample Type, Application, and End User Investment Opportunities in the Preeclampsia Laboratory Testing Market Key Developments and Innovations in Preeclampsia Laboratory Diagnostics Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in sFlt-1/PlGF Ratio Testing, Angiogenic Biomarker Assays, Automated Chemiluminescence Immunoassays, Diagnostic Reagents, and Maternal Risk Assessment Commercial Opportunities Arising from FDA-Authorized Biomarker Testing Developments in 2023 and 2025 Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Preeclampsia Laboratory Testing in Maternal Health, Early Diagnosis, and High-Risk Pregnancy Management Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory Approvals, Clinical Guidelines, and Reimbursement Policies Role of Proteinuria Testing, Angiogenic Biomarkers, and Automated Immunoassays in Preeclampsia Diagnosis Maternal Health Screening, Early Risk Assessment, Diagnostic Accuracy, and Laboratory Workflow Integration Trends Global Preeclampsia Laboratory Testing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Test Type: Proteinuria Testing sFlt-1/PlGF Ratio Testing Market Analysis by Biomarker: Urinary Protein Biomarkers Angiogenic Biomarkers Market Analysis by Technology: Immunoassays Automated Chemiluminescence Immunoassays Market Analysis by Sample Type: Urine Samples Blood Samples Market Analysis by Application: Preeclampsia Diagnosis Early Risk Assessment and Prediction Market Analysis by End User: Hospitals Diagnostic Laboratories Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Preeclampsia Laboratory Testing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Test Type, Biomarker, Technology, Sample Type, Application, and End User Country-Level Breakdown: United States Canada Mexico Europe Preeclampsia Laboratory Testing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Test Type, Biomarker, Technology, Sample Type, Application, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Preeclampsia Laboratory Testing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Test Type, Biomarker, Technology, Sample Type, Application, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Preeclampsia Laboratory Testing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Test Type, Biomarker, Technology, Sample Type, Application, and End User Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Preeclampsia Laboratory Testing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Test Type, Biomarker, Technology, Sample Type, Application, and End User Country-Level Breakdown: GCC Countries Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Thermo Fisher Scientific Roche Diagnostics Siemens Healthineers Revvity QuidelOrtho Randox Laboratories Beckman Coulter Abbott Laboratories Sysmex Corporation Competitive Landscape and Strategic Insights Benchmarking Based on Biomarker Assay Availability, Diagnostic Technology, Analyzer Compatibility, Regulatory Authorization, Reagent Portfolio, and Regional Presence Supplier Qualification, Clinical Validation, and Laboratory Quality-Control Capability Analysis sFlt-1/PlGF Ratio Testing and Angiogenic Biomarker Positioning Proteinuria Testing and Maternal Organ-Function Assessment Competitiveness Automated Immunoassay Platforms, Diagnostic Reagents, and Laboratory Workflow Integration Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Test Type, Biomarker, Technology, Sample Type, Application, End User, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Preeclampsia Diagnostic Testing Vendors Regulatory Authorization, Clinical Validation, Reimbursement, and Procurement Risk Analysis Technology Adoption Trends Across Proteinuria Testing, sFlt-1/PlGF Ratio Testing, Immunoassays, and Automated Chemiluminescence Immunoassays List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Test Type, Biomarker, Technology, Sample Type, Application, and End User (2025 vs. 2032) Global Preeclampsia Laboratory Testing Ecosystem and Diagnostic Value Chain Analysis